Menu
Retromer Therapeutics
Motivation: Despite multiple attempts to curtail progression of neurodegenerative diseases, few safe & efficacious therapeutics have come to market, underscoring the importance of accelerating novel approaches to a disease modifying therapeutic.
Lead Program(s): Retromer Therapeutics is pioneering a new class of therapeutics to treat neurodegenerative diseases by restoring the function of the endolysosmal trafficking system with preclinical programs in neurodegenerative diseases.
Pre-Clinical
Phase 1
Phase 2
Phase 3
